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Abstract 
Background: Cardiomyopathy is a devastating complication of obesity and type 2 diabetes mellitus (T2DM). It arises 
even in patients with normoglycemia (glycosylated hemoglobin, A1C ≤7 %). As obesity and T2DM are approaching 
epidemic levels worldwide, the cardiomyopathy associated with these diseases must be therapeutically addressed. 
We have recently analyzed the systemic effects of a 12‑week high fat diet (HFD) on wild type mice from the C57Bl/6 
(B6) strain and the wild type super‑healing Murphy Roths Large (MRL) mouse strain. The MRL HFD mice gained sig‑
nificantly more weight than their control diet counterparts, but did not present any of the other usual systemic T2DM 
phenotypes.
Methods: Cardiac pathology and adaptation to HFD‑induced obesity in the MRL mouse strain compared to the 
HFD C57Bl/6 mice were thoroughly analyzed with echocardiography, histology, qPCR, electron microscopy and 
immunoblots.
Results: The obese HFD C57Bl/6 mice develop cardiac hypertrophy, cardiomyocyte lipid droplets, and initiate an inef‑
fective metabolic adaptation of an overall increase in electron transport chain complexes. In contrast, the obese HFD 
MRL hearts do not display hypertrophy nor lipid droplets and their metabolism adapts quite robustly by decreasing 
pAMPK levels, decreasing proteins in the carbohydrate metabolism pathway and increasing proteins utilized in the 
β‑oxidation pathway. The result of these metabolic shifts is the reduction of toxic lipid deposits and reactive oxygen 
species in the hearts of the obese HFD fed MRL hearts.
Conclusions: We have identified changes in metabolic signaling in obese HFD fed MRL mice that confer resistance 
to diabetic cardiomyopathy. The changes include a reduction of cardiac pAMPK, Glut4 and hexokinase2 in the MRL 
HFD hearts. Overall the MRL hearts down regulate glucose metabolism and favor lipid metabolism. These adaptations 
are essential to pursue for the identification of novel therapeutic targets to combat obesity related cardiomyopathy.
Keywords: High fat diet, Diabetic cardiomyopathy, MRL mouse, pAMPK
© 2015 Roberts et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Human diabetic cardiomyopathy (DCM) is classified as 
left ventricular dysfunction without the usual predictors 
of cardiomyopathy such as hypertension or coronary 
artery disease [1, 2]. DCM is enigmatic because even 
diabetic patients with normoglycemia have an increased 
incidence of DCM [3, 4], and pre-diabetic patients are 
also prone to DCM [5, 6]. In addition, standard type 2 
diabetes mellitus (T2DM) treatments and preclinical 
experiments often reduce blood glucose and A1C levels 
but do not prevent DCM and sometimes even increase 
cardiac pathology [7]. Therefore the etiology of DCM is 
difficult to identify. Possible etiologic factors combining 
to cause DCM include obesity, hyperglycemia, oxidative 
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stress, lipotoxicity, inflammation, decreased autophagy 
and unsuccessful metabolic adaptation [7].
High fat diet (HFD)-fed mice recapitulate the etiology, 
pathology, and response to treatments similarly to those 
of T2DM patients. HFD-fed C57Bl/6 (B6) mice gain 
weight, develop insulin resistance, hyperglycemia, and 
DCM just like patients do. HFD and obesity in mice lead 
to cardiac remodeling, which is detected as increased 
heart mass, increased septal cross-section, increased car-
diac fibrosis, and decreased cardiac function [8]. Because 
MRL mice are globally resistant to HFD pathologies [9], 
we wanted to determine whether MRL mice develop car-
diomyopathy from HFD-induced obesity and possible 
compensatory protective mechanisms if they did not.
Both T2DM humans and HFD-fed mice respond well 
to increases in activated AMP-activated protein kinase 
(pAMPK), which reduces most of the HFD-mediated 
pathologies [7, 10, 11]. Increasing pAMPK is the target 
of multiple T2DM therapies, such as metformin, thiazo-
lidines, and exercise. However, the heart does not benefit 
from metformin treatment and many patients develop 
DCM despite maintaining normoglycemia [3, 4, 7, 12]. 
The cardiac pathology of T2DM is therefore clearly sep-
arate from the systemic pathology, many patients with 
normoglycemia still develop DCM, many T2DM patients 
die of cardiovascular diseases [7]. Therefore, this aspect 
of T2DM must be further investigated. The obese HFD 
fed MRL mice, which we now show are resistant to obe-
sity-related cardiac remodeling, will provide additional 
insights into the prevention of obesity-induced cardiac 
pathology.
The obese HFD MRL mice remain pathology free 
despite having gained as much weight as the HFD B6 
mice [9]. The HFD MRL mice do not become hypergly-
cemic, and respond normally to insulin and glucose toler-
ance tests. The control diet (CD) MRL skeletal muscles 
contain increased basal AMPK and pAMPK [13]. The 
HFD MRL skeletal muscles respond and adapt to the 
HFD by increasing their AMPK and pAMPK levels even 
more than the basal levels [9]. pAMPK is central to skel-
etal muscle metabolism at a number of important deci-
sion points [14]. During either fasting or routine exercise 
regimes, when the skeletal muscle’s ATP levels decrease, 
AMPK is activated by phosphorylation and initiates 
catabolism to increase ATP levels and inhibits anabo-
lism to conserve ATP. As part of the catabolic processes, 
increased pAMPK, causes Glut4 translocation to the cel-
lular membrane which will increase glucose internaliza-
tion [15], causes increased levels of glycolysis [16], which 
can increase ATP production without requiring oxygen 
and also causes increases in β-oxidation rates [17]. All of 
these pAMPK-elicited metabolic changes benefit patients 
with T2DM.
The 12  weeks HFD B6 control mouse hearts display 
essential aspects of DCM. These mouse hearts, as a 
whole, and as individual cardiomyocytes, develop hyper-
trophy. No molecular attempts to compensate for the 
HFD diet are displayed by the B6 cohort; therefore the 
hearts develop lipid deposits and fibrosis. Alternatively, 
the hearts from the obese HFD MRL mice metabolically 
adapt and thereby prevent DCM. The HFD MRL hearts 
completely down-regulate their carbohydrate metabo-
lism pathways and shift to lipid metabolism. This adapta-
tion strategy works well for the MRL mice as they do not 
develop DCM despite pronounced weight gain, especially 
in the usually pathogenic visceral fat deposits. It is these 
experimentally identified metabolic adaptations that will 
inform future therapies for patients suffering from DCM.
Initially we hypothesized that, like the skeletal mus-
cles [9] and liver tissues (Gonzalez M., unpublished 
observations), the HFD MRL cardiac tissues would have 
increased levels of pAMPK. Surprisingly, our original 
hypothesis was not supported by the data. Instead the 
data identifies that the HFD MRL cardiac tissues have 
decreased pAMPK. Despite this being opposite numer-
ous published manuscripts, this pAMPK reduction 
is correlated with improved metabolic flexibility and 
improved function in the obese HFD MRL mice.
Methods
Animal protocols
The experiments and procedures in this study were 
approved by the University of Illinois at Chicago (UIC) Insti-
tutional Animal Care and Use Committee (IACUC). Male 
mice from the C57BL/6J (B6), and MRL/MpJ (MRL), with 
an intact Fas gene, strains were housed in the same animal 
facility on a 14 h light, 10 h dark cycle with water ad libitum. 
At 3 weeks of age, mice were assigned either a chow (CD, 
7012  Teklad LM-485 Mouse/Rat Sterilizable Diet, Harlan 
Laboratories, Indianapolis, IN, USA) or high fat diet (HFD, 
60 % kcal from fat, D12492 Research Diets Inc, New Brun-
swick, NJ, USA). This ad  libitum diet was maintained for 
12 weeks through the end of the experiment. The mice were 
euthanized following UIC and nationally accepted protocols 
with prolonged carbon dioxide exposure followed by cervi-
cal dislocation. Tissue samples were harvested immediately. 
Samples designated for immunoblotting were flash frozen in 
liquid nitrogen and stored at −80 °C until processed. Tissue 
samples for immunofluorescence were placed in optimal 
cutting temperature (OCT) compound and then frozen in 
liquid nitrogen cooled isopentane.
Echocardiography
Echocardiography was performed by Dr. Robert Gaffin of 
the UIC Center for Cardiovascular Research. Mice were 
anesthetized using 3  % isoflurane, which was decreased 
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to 2 % for anesthesia maintenance. Cardiac morphologi-
cal, diastolic, and systolic parameters were assessed using 
the VisualSonics Vevo 770 (VisualSonics, Toronto, Can-
ada) with a RMV707B (30 MHz) scanhead and the built-
in echocardiography software.
Histology and immunofluorescence
The previously frozen tissues were sectioned at seven 
microns on a cryostat. Tissue samples for Picro Sirius 
Red were sectioned at 20 microns and processed by the 
UIC Research Resources Center (RRC) Histology Core. 
Heart sections from all four groups were placed on the 
same slide to minimize artifacts. ImageJ was utilized to 
quantify the percentage of red staining per image.
The slides for immunofluorescent staining were fixed 
for 20 min in −20 °C MetOH, washed 3 times in 4 °C PBS 
for 3 min, and blocked in 5 % FBS in PBS for 15 min at 
room temperature. The slides where incubated with anti-γ 
sarcoglycan (1:100, Novocastra Labs, Buffalo Grove, IL, 
USA), anti-Glut4 (1:50, EMD Millipore, Darmstadt, Ger-
many) or anti-fibronectin (1:100, Sigma, St. Louis, MO, 
USA) in PBS with 5 % fetal bovine serum for 1 h at room 
temperature, then aspirated and washed three times for 
15  min in 4  °C PBS. The secondary antibodies (Invitro-
gen) at 1:500 in 5 % FBS in PBS were placed onto the slide 
for 1  h at room temperature in the dark. After another 
series of washes, the slides were mounted using Vectash-
ield mounting solution, with DAPI (Vector Laboratories, 
Burlingame, CA, USA). Heart sections from all four slides 
were affixed to a single slide to minimize artifacts. ImageJ 
was used to get the average intensity of staining across 
each section or along a line segment.
Cardiomyocyte cell size quantification
Cardiomyocyte cell size was quantified by highlighting 
the γ-sarcoglycan staining on the tissue images using 
a combination of GIMP (http://www.gimp.org/) and 
ImageJ (http://rsbweb.nih.gov/ij/). In brief, the stain was 
outlined and used to generate an image of uniformly 
black cells on a white background. The minimum diam-
eter was then quantified in ImageJ and used to calculate 
area. One septal image (100× initial magnification) per 
animal, and at least four animals per group were quan-
tified; the averages per group were then statistically 
compared.
Immunoblot analysis
Expression levels of specific proteins were assessed by 
immunoblotting. Each tissue sample was added to 250 μl 
lysis solution (20 mM HEPES pH 7.4, 10 mM NaF, 50 mM 
β-glycerol phosphate, 2  mM EGTA, 1  % Triton X100, 
10 % glycerol, 2.5 μl of sodium orthovanadate, 2.5 μl of 
DTT, 2.5  μl of Halt Protease and Phosphatase Inhibi-
tor Cocktail (100×, Thermo Scientific, Hanover Park, 
IL, USA). The mixture was homogenized on ice using a 
TissueRuptor (Qiagen, Venlo,  Netherlands). The solu-
tion was then spun at 4 °C for 10 min. Supernatant pro-
tein concentrations were determined by Bradford assay 
(Thermo Scientific Coomassie, Bradford Protein Assay 
Kit). Fifty ug of protein were heated for 5 min at 100 °C 
and loaded onto 12  % acrylamide gels (Mini-Protean 
TGX, Biorad, Hercules, CA, USA). Gels were transferred 
onto PVDF membrane using a semi-dry transfer system 
(iBlot, Invitrogen, Camarillo, CA, USA). Five percent 
reconstituted non-fat dairy milk (NFDM) in tris-buffered 
saline with 0.1 % tween-20 (TBST) was used to block the 
gels for 15 min. The membranes were incubated at 4  °C 
overnight in 5 % NFDM/TBST with primary antibodies 
[anti-AMPK, anti-pAMPK, and PGC-1α (1:1000, Cell 
Signaling Technology, Danvers, MA, USA); anti-ACC, 
anti-pACC, fibronectin (1:500, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA); anti-HKII (1:5000, Millipore, 
Billerica, MA, USA); VDAC, Oxidative Phosphoryla-
tion antibody cocktail (1:1000, Abcam, Cambridge, MA, 
USA), Glut4 (1:500, EMD Millipore, Darmstadt, Ger-
many), and γ-sarcoglycan (1:1000, Novocastra Labs, 
Buffalo Grove, IL, USA)]. Three 15-min washes with 
1× TBST were performed after the primary antibody was 
removed. Blots were then incubated at room tempera-
ture for 1  h with horseradish peroxidase (HRP) conju-
gated species specific secondary antibodies (Invitrogen, 
1:2500 in 1×  TBST). Following another set of washes 
bound HRP was detected with ECL Prime (Amersham, 
GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and 
a Chemidoc (Biorad Life Sciences Group, Hercules, CA, 
USA). Protein bands at the appropriate size from at least 
six animals per group were quantified using ImageJ. Pon-
ceau staining was used to verify loading for each gel and 
γ-sarcoglycan, a membrane localized protein, immunob-
lotting of sister gels was used for normalization. To com-
pare across gels, bands from each gel were normalized to 
the CD B6 average for that protein.
Electron microscopy
Freshly isolated heart apexes from one animal of each 
group were delivered to the electron microscopy facility 
of the UIC RRC. Micrographs were captured in a blinded 
manner at 11,600× and 34,400× magnifications.
Quantitative PCR
Previously published methods were used to quantify the 
amount of mitochondrial genome represented by subunit 
II of cytochrome C and using the nuclear gene succinate 
dehydrogenase subunit A as a control [13, 18].
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Statistics
Student t tests were performed in Microsoft Excel com-
paring the appropriate groups. Values <0.05 were consid-
ered significant between the groups being examined.
Results
We subjected the MRL and control B6 mouse strains to 
12 weeks of high fat diet (HFD) or control diet (CD) to 
investigate the abilities of the MRL mouse hearts to met-
abolically adapt to HFD. The HFD fed MRL mice gained 
significantly more weight than the CD fed MRL mice [9], 
and the HFD MRL mouse hearts demonstrated altered, 
beneficially adapted metabolic changes. Because the 
HFD mouse model mirrors human T2DM, identifying 
and investigating these beneficial metabolic changes will 
be essential for future diabetic cardiomyopathy (DCM) 
therapies.
HFD MRL mouse hearts are protected against high fat 
diet‑induced cardiac remodeling
The hearts from the four mouse groups (CD B6, HFD B6, 
CD MRL and HFD MRL) were analyzed with histologic 
and immunofluorescence staining. The HFD B6 hearts 
displayed increased red staining with Picro Sirius Red, 
a fibrosis indicator, when compared to the three other 
groups (Fig. 1a). The Picro Sirius Red images were quan-
tified and demonstrated a significant increase of collagen 
in the HFD B6 cardiac tissue (Fig.  1b). Similarly, when 
stained with fibronectin, the HFD MRL hearts stained 
comparably to the B6 CD and MRL CD hearts; while the 
HFD B6 hearts contained many regions of positive stain-
ing, further demonstrating increased fibrosis (Fig.  1c). 
In particular, the HFD B6 hearts contained numerous 
instances of perivascular fibrosis, an early stage in fibrosis 
progression (arrow in Fig.  1c) and interstitial fibrosis, a 
more advanced stage of the fibrotic process (asterisk in 
Fig. 1c). These images were also quantified and indicated 
an increase of fibronectin in the B6 HFD hearts (Fig. 1d). 
To quantify the increased fibrosis identified in the HFD 
B6 mice, an immunoblot of fibronectin was also per-
formed. In support of the histology and immunofluores-
cence, the immunoblot identified that the HFD B6 mice 
had significantly increased fibrosis (B6 CD versus B6 
HFD p = 0.02, immunoblot Fig. 1e, and quantified in 1f ). 
Interestingly, this characteristic of cardiac remodeling 
was absent in the HFD MRL hearts when compared to 
their CD counterparts. Surprisingly, both groups of MRL 
hearts trended to an increase in fibronectin when com-
pared to the B6 mice. Based upon these initial intrigu-
ing findings, we pursued cardiac characterization of the 
metabolically unique MRL mice fed the HFD. Identifi-
cation of the mechanism causing HFD cardiac fibrosis 
resistance is of the utmost importance for obese and 
T2DM patients.
To further investigate cardiac remodeling, hypertro-
phy was evaluated by (1) left ventricle mass (obtained 
from echocardiography) over tibia length and (2) car-
diomyocyte size (quantified on immunofluorescent 
staining). Only the HFD B6 animals demonstrated patho-
logic cardiac hypertrophy as their left ventricle masses/
tibia lengths significantly increased over the B6 CD 
controls (Fig.  2a). The HFD MRL left ventricle masses 
were not significantly larger than the CD MRL left ven-
tricle masses. The MRL hearts are not pathologically 
enlarged; the size is a physiologic compensation for their 
larger body size. Tibia lengths were utilized as the nor-
malizing factor instead of body weight because the HFD 
mice gained so much weight this normalization actually 
showed a decrease of cardiac size in the HFD mice. We 
also identified significantly larger cardiomyocytes in the 
HFD B6 mice compared to the three other groups (quan-
tified in Fig.  2b and representative images Fig.  2c). The 
B6 HFD cardiomyocytes were larger than their CD coun-
terparts (1152 ± 108 versus 880 ± 148 μm2, p = 0.025, 
N > 3) and larger than the HFD MRL cells (1152 ± 108 
versus 937 ± 130 μm2, p = 0.032, N > 3).
Further evidence of cardiac remodeling in the B6 HFD 
mice comes from additional echocardiography morpho-
metric characteristics. The left ventricular anterior wall 
during diastole (LVAWd) and during systole (LVAWs) 
were both significantly increased in the B6 HFD fed ani-
mals compared to the B6 CD mice (Fig.  2d, e; Table  1). 
This is indicative of the expected hypertrophic cardiac 
remodeling in response to HFD. The HFD MRL mice 
however showed significant decreases in these two mor-
phologic characteristics compared to their CD MRL 
counterparts. Other morphometric values that were 
obtained through echocardiography were not signifi-
cantly different between the diets within either strain 
(Table 1). Future investigations will identify the beneficial 
metabolic adaptations in the MRL heart tissue for future 
therapies in humans.
MRL mouse diastolic function apparently benefits 
from high fat diet‑induced obesity
The MRL left ventricles responded favorably to the HFD 
as the echocardiographic parameters indicate increased 
pliability and less fibrosis. E wave deceleration time 
(E DT) is an inverse measure of left ventricle stiffness; 
increasing deceleration time indicates decreasing stiff-
ness. MRL HFD animals had significantly longer E DT 
times than their chow diet controls (p =  0.03, Table  1), 
while there was no difference between the B6 CD and 
B6 HFD animals. From this data it also appears that the 
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MRL CD hearts are more rigid as their E DT was signifi-
cantly lower than the B6 CD hearts (p = 0.0068, Table 1).
The E′/A′ ratio is an echocardiographic measure of left 
ventricular filling. There was no difference in the E′/A′ 
ratio between the two B6 groups. MRL mice on the HFD 
diet however had a significantly lower ratio than their CD 
counterparts (p = 0.004, Table 1). This decrease brought 
the E′/A′ ratio of the HFD MRL mice close to the chow 
B6 ratio, bringing the ratio to a more normative level. 
From the E′/A′ ratio it again appears as though the MRL 
hearts are benefited by the HFD.
Neither ejection fraction (EF) nor fractional shorten-
ing (FS) were affected in either mouse strain by the HFD 
(Table 1). Both of the MRL animal groups had higher EF 
and FS than the B6 animals but this is simply physiologi-
cal, again due to the larger MRL animals. In addition, nei-
ther mouse strain developed hypertension as a result of 
the 12 weeks of HFD when compared to the age matched 
CD counterparts (data not shown). The lack of hyperten-
sion is surprising in light of the HFD-enhanced weight 
gain displayed by both mouse strains.
MRL cardiac tissues have lower activated pAMPK levels
AMPK and its activated form phosphorylate AMPK 
(pAMPK) function as sensors of available ATP levels in 
cells. AMPK is phosphorylated to pAMPK when the ratio 
of ADP to ATP shifts in favor of the lower energy ADP. 
pAMPK in turn facilitates energy production and energy 
conservation [19]. CD MRL mice have significantly 
lower levels of cardiac pAMPK than their CD B6 coun-
terparts (p = 0.010, blot in Fig. 3a, control blot in Fig. 3b 
and quantified in Fig.  3c). This pattern of decreased 
pAMPK in MRL cardiac tissue remains at the conclusion 
of the HFD protocol: the HFD MRL cardiac tissues have 
Fig. 1 The HFD B6 hearts present with fibrosis, which is absent in the HFD MRL hearts. a Picro Sirius Red staining was enhanced in the HFD B6 
hearts compared to the other three groups. Initial magnification ×100. Histogram of ImageJ quantification follows, N = 3, bar represents p < 0.05. b 
Representative immunofluorescent microscopy of fibronectin stained tissues confirms the increased fibrosis in HFD B6 hearts. Initial magnification 
×100. Histogram of ImageJ quantification follows, N = 3, bar represents p < 0.05. c Immunoblot of fibronectin verifies increased fibrosis in the HFD 
B6. d Control γ‑sarcoglycan immunoblot. e Quantification (N = 6, B6 CD versus B6 HFD p = 0.026, B6 CD versus MRL CD p = 0.038)
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significantly lower levels of pAMPK than the HFD B6 
animals (p = 0.025). No significant difference was seen in 
either strain between the CD and HFD animals.
Although few examples of transcriptional regulation 
of AMPK exist, our current data proves that this does 
occur in cardiac tissues. The MRL hearts have signifi-
cantly higher levels of AMPK alpha chains than the B6 
hearts for both diet groups (Fig. 3d, quantified and nor-
malized to γ-sarcoglycan in 3e, B6 CD versus MRL CD 
p = 0.005 and B6 HFD versus MRL HFD p = 0.038). In 
addition, HFD decreases the AMPK alpha chains in the 
MRL groups (p  =  0.025). Identifying the transcription 
factors which modulate AMPK subunit expression will 
also prove useful in therapies directed against multiple 
human diseases. Although AMPK appears to be under 
transcriptional control in the cardiac tissue we also pre-
sent the pAMPK to AMPK ratios. Both groups of B6 
mice contained more pAMPK/AMPK than the MRL car-
diac tissues (Fig. 3f ).
Protein levels indicate that MRL hearts perform decreased 
carbohydrate metabolism
MRL CD mice were found to have significantly lower 
levels of total Glut4 protein present in their hearts 
than the B6 CD animals (p =  0.003, Fig.  4a). The HFD 
hearts from both strains contained less Glut4 than the 
CD hearts, with the HFD MRL animals containing the 
least (p =  0.001 versus the HFD B6 mice, Fig.  4a, con-
trol γ-sarcoglycan in Fig.  4b, and quantified in Fig.  4c). 
Because membrane localization of Glut4 is critical for its 
Fig. 2 The hearts from HFD B6 mice display morphologic pathologies. a The echocardiography determined left ventricular (LV) mass normalized 
to tibia length is larger in the HFD B6 mice when compared to the CD B6 mice (p = 0.015, N > 8). b Similarly, the immunofluorescent determined 
cell size is larger in the HFD B6 mice when compared to the three other mouse groups (B6 CD versus B6 HFD, p = 0.025, B6 HFD versus MRL HFD 
p = 0.032, N > 3). c Representative cell sizes visualized by γ‑sarcoglycan staining. d, e Echocardiography also revealed increases in left ventricle 
anterior wall during diastole and systole in the HFD B6 hearts compared to the CD B6 hearts (N > 8, bars indicate p < 0.05)
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function heart tissue immunofluorescence was under-
taken on the four mouse groups. The B6 heart cells 
demonstrated increased Glut4 membrane localization 
compared to the MRL groups (representative images 
in Fig.  4d, quantified in Fig.  4e). We quantified the sig-
nal intensity along a line crossing the plasma membrane 
(white lines in the Fig. 4d images). We reasoned that this 
intensity would reflect membrane localization of Glut4. 
The line graphs show increased membrane signal in the 
B6 hearts (Fig. 4e) compared to the MRL hearts.
Supporting decreased carbohydrate metabolism, the 
CD MRL mice were also found to have lower hexoki-
nase II (HKII) levels than the CD B6 mice (p  =  0.000, 
blot Fig.  5a, γ-sarcoglycan control Fig.  5b and quanti-
fied in Fig.  5c). The HFD MRL mice also had signifi-
cantly decreased HKII compared to the HFD B6 mice 
(p = 0.001). The B6 mice fed a HFD had lower levels of 
HKII than their chow counterparts (p = 0.013). The MRL 
mice demonstrated no difference in HKII levels between 
the CD and HFD cohorts.
MRL hearts preferentially utilize fatty acid metabolism
As the CD MRL hearts have less carbohydrate metabolic 
proteins, we expected an increase in the proteins of the 
fatty acid metabolic cascade. We therefore assessed the 
levels of acetyl-CoA carboxylase (ACC and pACC), the 
key regulatory protein in the fatty acid metabolic process. 
Decreased ACC decreases the amount of malonyl-CoA, 
ultimately increasing CPT1-mediated fatty acid trans-
port into the mitochondria [2]. By immunoblot we found 
a significant decrease of ACC in the HFD MRL hearts 
compared to the HFD B6 hearts (immunoblot Fig.  6c, 
quantified in Fig.  6d, p =  0.033) indicating a likelihood 
of increased fatty acid oxidation in the MRL HFD hearts. 
Because of the large increase of ACC in the B6 HFD 
hearts compared to the B6 CD hearts (p = 0.013), we can 
also reason that the B6 HFD hearts are saturated with 
free fatty acids and have therefore decreased their fatty 
acid imports. These data are consistent with the MRL 
hearts performing less carbohydrate metabolism and 
increased β-oxidation in CD conditions and this propen-
sity is increased in the HFD situation.
Hearts of HFD-fed animals usually store fat in the 
form of intracellular lipid droplets because they cannot 
metabolize all of the imported fat. By electron micros-
copy, cytoplasmic and mitochondrial lipid droplets are 
obvious in heart apex samples in the HFD B6 heart tis-
sues, while the HFD MRL heart tissue is devoid of these 
lipid droplets (Fig.  7). The HFD MRL cardiomyocytes 
have successfully adapted to HFD metabolism without 
detectable pathologic cardiac consequences. In addition, 
the mitochondrial cristae of the HFD B6 hearts look mal-
formed compared to the three other samples. All hearts 
were harvested and processed simultaneously, decreas-
ing the chances of these differences being artifacts. The 
functional implications of the altered cristae are yet to be 
explored.
MRL cardiac tissues have increased levels of mitochondrial 
DNA
Quantitative PCR was used to compare the ratios of 
mitochondrial and nuclear genomes. The qPCR data 
Table 1 Echocardiography parameters for the four mouse groups
Italics indicate significance (p < 0.05) versus the control diet group of the same strain
N > 14
LVAWd left ventricular anterior wall in diastole, LVAWs in systole, LVIDd interior diameter in diastole, E DT E wave deceleration time, EDV left ventricular end diastolic 
volume
B6 CD B6 HFD MRL CD MRL HFD
Morphological
 LVAWd (mm) 0.70 ± 0.08 0.81 ± 0.08* 1.07 ± 0.11 0.95 ± 0.15*
 LVAWs (mm) 0.97 ± 0.16 1.14 ± 0.13* 1.58 ± 0.22 1.38 ± 0.20*
 LVIDd (mm) 3.87 ± 0.29 3.91 ± 0.28 4.12 ± 0.25 4.17 ± 0.34
Diastolic
 E DT (ms) 20.04 ± 3.69 19.63 ± 4.15 13.59 ± 5.02 19.04 ± 5.77
 E/A 1.55 ± 0.32 1.81 ± 0.72 2.00 ± 0.55 2.13 ± 0.52
 E′/A′ 1.05 ± 0.31 1.18 ± 0.61 1.33 ± 0.27 1.03 ± 0.16*
 EDV (μL) 65.86 ± 12.29 67.84 ± 11.24 75.54 ± 10.05 78.26 ± 13.37
Systolic
 EF % 56.33 ± 4.25 56.67 ± 8.84 70.25 ± 8.97 64.63 ± 11.30
 FS % 29.03 ± 2.69 29.58 ± 6.67 39.91 ± 7.59 35.74 ± 8.94
 HR 439.00 ± 40.69 448.77 ± 54.40 441.90 ± 54.45 441.08 ± 35.52
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indicated that the MRL hearts have increased mito-
chondrial genomes per nuclear genome when com-
pared to the diet matched controls (Fig.  8a, CD B6 v 
CD MRL p = 0.002, HFD B6 v HFD MRL p = 0.043). A 
further method of quantifying mitochondria is to meas-
ure mitochondrial protein concentrations. Immunob-
lots of VDAC, a mitochondrial outer membrane protein 
were used. No differences were detected between the 
mouse groups in VDAC quantity (VDAC immunoblot 
Fig.  8b, γ-sarcoglycan control Fig.  8c, and quantified in 
Fig.  8d). To further analyze the mitogenesis portion of 
mitochondrial levels, PGC-1α levels were assessed in the 
hearts from the four mouse groups. No differences were 
detected between any of the groups (data not shown). 
The increase of mitochondrial DNA in the MRL hearts 
may be the proximal cause of the HFD resistant pheno-
type, this hypothesis remains to be determined by further 
experimentation.
Fig. 3 MRL hearts contain reduced amounts of pAMPK and AMPK. a Representative immunoblot of the phosphorylated α subunits of AMPK in 
mouse hearts. b γ‑Sarcoglycan loading control. c pAMPK quantification normalized to γ‑sarcoglycan and the B6 CD average (N = 15, B6 CD versus 
MRL CD p = 0.010, B6 HFD versus MRL HFD p = 0.025). d Representative immunoblot of the α subunits of AMPK in mouse hearts. e AMPK quantifi‑
cation normalized to the same γ‑sarcoglycan blot as above and the CD B6 average (N = 9, B6 CD versus MRL CD p = 0.005, B6 HFD versus MRL HFD 
p = 0.038, MRL CD versus MRL HFD p = 0.037). f pAMPK/AMPK (N = 6)
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Electron transport chain (ETC) complexes are differentially 
affected by the HFD
As our hypothesis is that the MRL cardiomyocytes are 
chronically stressed energetically we also assessed one 
component of each ETC complex by immunoblot. In 
the control B6 mouse strain all assessed members (com-
plex I subunit NDUFB8, complex II the 30 kDa subunit, 
complex III the core protein 2, complex IV subunit I, and 
complex V the alpha subunit) of the five ETC complexes 
were upregulated by HFD, and four of the five upregu-
lated components are significantly increased (Fig.  9). 
The MRL hearts adapt to the HFD differently and only 
upregulated the complex III and complex V components 
significantly. We have not yet conducted activity assays, 
analyzed reactive oxygen content or quantified ATP lev-
els in these hearts, so in-depth metabolic conclusions 
cannot yet be made.
Discussion
The cardiac responses to HFD in the B6 and MRL wild 
type mouse strains were analyzed for DCM phenotype. 
As expected, the HFD B6 mice developed key features 
of DCM: hypertrophy, morphometric changes, and lipid 
accumulation. In contrast, despite gaining a similar 
amount of weight as the HFD B6 mice [9], the wild type 
MRL mice were resistant to the HFD and did not develop 
any features of DCM. Remarkably, the HFD MRL hearts 
contained significantly less pAMPK by immunoblot than 
the HFD B6 hearts. The MRL mice also reduced their 
carbohydrate metabolic enzymes while increasing the 
enzymes required for β-oxidation.
Multiple assays verified that the HFD B6 mice were 
susceptible to the diabetic cardiomyopathy (DCM) 
pathologies associated with HFD-induced obesity. The 
Fig. 4 Glut4 is significantly reduced in the MRL hearts. a Representative immunoblot of Glut4 in mouse hearts. b γ‑Sarcoglycan loading control. 
c Glut4 quantification normalized to γ‑sarcoglycan (N = 9, B6 CD verses MRL CD p = 0.003, B6 HFD versus MRL HFD p = 0.001). d Representative 
immunofluorescence of Glut4 in the cardiac septum, original magnification ×100. e Brightness intensity of lines drawn (white dashes in Fig. 5d) 
across the plasma membranes
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cardiac tissues were stained for various markers of fibro-
sis. By Picro Sirius Red staining the B6 HFD hearts con-
tained the most positive red regions followed by the MRL 
HFD mice and then the CD control hearts contained the 
least. A very similar trend was seen when sections were 
stained for fibronectin. However immunoblots with the 
same fibronectin antibody provided inconsistent results. 
The ultimate reason for this discrepancy could be as 
simple as the denaturing conditions of the gel versus 
the largely unmodified proteins in the immunofluores-
cence. The discrepancy could also arise from immuno-
fluorescence image selection. We feel this is unlikely as 
we chose the images using the blue (DAPI, nuclear) filter 
set and looking for blood vessels to compare perivascu-
lar fibrosis. The increased fibronectin by immunoblot in 
the CD MRL hearts may reflect the slight level of meta-
bolic stress these hearts are subjected to, due to the mito-
chondrial heteroplasmies. Additional experiments are 
being initiated to identify the basal metabolic differences 
between these two mouse strains. Despite the inconsist-
ent results, when considering all of the data it is appar-
ent that the HFD B6 hearts are pathogenically affected, 
while the HFD MRL hearts are beneficially adapting to 
the HFD stress.
By echocardiography, the ratios of left ventricle mass to 
tibia length were increased in the HFD B6 compared to 
CD B6 mice. Tibia length was utilized as the normaliz-
ing factor because the HFD animals gained such a large 
amount of weight that this would misrepresent the heart 
mass increases. Tibia length did not change between the 
diets after the 12  weeks of diet intervention (data not 
shown). In addition, quantitation of histology sections 
demonstrated larger cardiomyocytes in the HFD B6 mice 
compared to their CD counterparts. Furthermore, addi-
tional morphologic differences revealed by echocardiog-
raphy demonstrated increased values only in the HFD B6 
mice compared to the CD B6 mice. In contrast, the HFD 
MRL mice were not statistically different than their CD 
counterparts in any of these parameters indicating the 
MRL resistance to HFD. By left ventricular size to tibia 
length ratios, hearts from both MRL diet groups were 
larger than the B6 hearts. This is a physiologic increase 
due to the larger MRL animal size [9] and not due to 
Fig. 5 Hexokinase II is also reduced in the MRL cardiac tissue. a Rep‑
resentative immunoblot of HKII in the heart tissues. b γ‑Sarcoglycan 
loading control. c Quantification of HKII normalized to γ‑sarcoglycan 
and B6 CD quantities (N = 12, B6 CD verses MRL CD p = 0.000, B6 
HFD versus MRL HFD p = 0.001, and B6 CD versus B6 HFD p = 0.013)
Fig. 6 Decreased MRL cardiac ACC indicates increased fatty acid 
metabolism. a pACC immunoblot. b Quantification normalized to 
γ‑sarcoglycan shows the MRL tissues have reduced pACC (N = 6, B6 
HFD versus MRL HFD p = 0.011). c ACC immunoblot. d Quantification 
normalized to γ‑sarcoglycan shows the MRL tissues have reduced 
ACC (N = 6, B6 HFD versus MRL HFD p = 0.033, B6 CD versus B6 HFD 
p = 0.013)
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pathology because the size is not further increased by 
HFD.
The echocardiography data reveals a functional pres-
ervation and in some cases an improvement in the HFD 
MRL hearts. Although surprising, this protection may be 
caused by a chronic reduced mitochondrial efficiency [13, 
18], due to two mitochondrial heteroplasmies identified 
in these mice [20]. Heteroplasmy describes the multiple 
copies of a mitochondrial genome which contains both 
wild type and polymorphic sequences. Therefore, this 
leads to chronic cardiomyocyte metabolic stress which in 
this situation is beneficially adaptable to the HFD. One of 
the manifestations of this stress is an increased glycolysis 
rate in the MRL cells compared to B6 heart cells when 
glucose is the substrate [18]. This data corroborates our 
results, which indicate that MRL cardiomyocytes favor 
lipids as substrates and actually functionally improve on a 
HFD. These data and this model are currently being fur-
ther investigated.
Previous data indicate that most mice receiving a HFD 
will increase their lipid metabolism and decrease their 
carbohydrate metabolism [21]. The HFD fed MRL mice 
appear to take these metabolic shifts to an extreme. It 
has been proposed that pharmacologically reversing 
these changes; increasing glucose utilization and decreas-
ing lipid metabolism will be beneficial to heart failure 
patients [21]. The health of the MRL mouse hearts indi-
cates the opposite may be true and increased reliance 
upon lipid metabolism is the healthy adaptation. If these 
extreme metabolic shifts cause the HFD MRL hearts to 
remain healthy will be analyzed in future experiments.
The decreased level of AMPK and pAMPK in the 
healthy HFD MRL hearts is unexpected. A number of 
studies have demonstrated that increased pAMPK is 
usually associated with, or directly causes improved car-
diac function [22]. There is also evidence that increased 
pAMPK benefits mouse models of DCM [23]. Impor-
tantly, Steinbusch et  al. [24], showed that viral over-
expression of a constitutively active AMPKα2 in primary 
cultures of insulin resistant cardiomyocytes significantly 
protected cellular metabolism. These authors also iden-
tified that increasing pAMPK activity does not correct 
all high lipid media consequences. For example, the 
Fig. 7 Representative electron micrographs of cardiac muscle from 
the septum identify lipid droplets in only the HFD B6 mice (upper 
right panel). The droplets were found cytoplasmically located (asterisk) 
or within the mitochondria (plus). Bars 0.5 μm
Fig. 8 Mitochondrial differences in the two mouse strains. a The 
hearts from MRL mice contain increased mitochondrial genomes 
when normalized to nuclear DNA (N = 14, CD comparisons p = 0.002 
and HFD comparisons p = 0.043). b However, quantification of VDAC 
immunoblots demonstrated no change in the outer mitochondrial 
membrane protein (N = 6). c Control to γ‑sarcoglycan immunoblot. 
d VDAC normalized to γ‑sarcoglycan (N = 6)
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cardiomyocytes with over expression of pAMPK main-
tained high palmitate uptake and triglyceride accumu-
lation. The authors concluded that increasing pAMPK 
rectified glucose metabolism but not lipid metabolism. 
Our current data is consistent with other mechanisms 
beyond pAMPK activation controlling cardiac lipid 
metabolism. Knowledge of these mechanisms will pro-
vide additional therapeutic targets for humans suffering 
from T2DM and DCM.
These novel MRL pathways would cause the MRL 
hearts to favor lipid metabolism over carbohydrate 
metabolism to a larger extent than other mouse strains. 
By increasing their lipid metabolism, excess lipids would 
not be stored in the hearts causing lipotoxicity as usually 
occurs in HFD B6 fed mice [25]. We hypothesize that the 
CD MRL heart tissue is in a chronic state of metabolic 
stress due to less efficient electron transport chain activi-
ties as a result of the two mitochondrial heteroplasmies. 
Therefore we can view the MRL tissues as preconditioned 
for the HFD diets and completely adaptable to the added 
stress of a HFD. A schematic of this working model is 
presented in Fig.  10, black arrows indicating increase 
or decrease of indicated proteins for B6 HFD mice and 
green arrows indicating MRL HFD protein changes.
In support of the MRL hearts favoring lipid metabo-
lism are the changes in key metabolic proteins between 
Fig. 9 The B6 and MRL mouse strains respond differently to HFD mediated metabolic stress. Protein levels of single components of the electron 
transport chain’s complex I through V were assessed. The B6 hearts increased levels of all complex members, while the MRL hearts only significantly 
raised the levels of complex members III and V (N = 3)
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the two mouse strains. The MRL hearts, regardless of 
diet, have significantly reduced total and membrane 
localized Glut4. Glut4 is a key protein in cellular entry 
of glucose and its translocation to the cell membrane 
is a well-known function of pAMPK [26]. Therefore, 
the decreased Glut4 translocation is consistent with 
reduced pAMPK in the MRL hearts. A second key pro-
tein in carbohydrate metabolism is hexokinase II (HKII) 
which phosphorylates glucose and thereby locks it into 
the cell. HKII is also significantly reduced in the MRL 
hearts. Additional assessment of an important step in 
lipid metabolism revealed key proteins involved in inhib-
iting lipid transport to be downregulated in the MRL 
heart tissues. Combined, these data further support the 
hypothesis that the MRL hearts down regulate glucose 
metabolism and favor lipid metabolism more than B6 
hearts. Therefore it is clear that the MRL hearts are meta-
bolically adapting to the HFD stress and are responding 
to the pathogenic signals in favorable ways.
Previous reports indicate that MRL tissues con-
tain increased mitochondrial genomes compared to 
B6 control strain [13, 18]. We sought to identify if the 
HFD caused further changes in mitochondrial genome 
quantity in the cardiac tissues. By qPCR we identified 
significantly increased mitochondrial to nuclear genome 
ratios in both MRL mouse groups. This data was not 
supported by VDAC—an outer mitochondrial mem-
brane protein—expression. A possible explanation is 
that the MRL mitochondrial genomes are more densely 
arranged within the matrix, therefore the DNA content 
will increase without increasing the membrane protein 
amount. This could be a further indication of chronic 
low-level stress in the MRL cardiac cells.
There is much discussion whether murine HFD can 
cause DCM. Many publications demonstrate DCM after 
murine HFD feeding [8]. Mice on a chronic HFD gain 
more weight than their CD counterparts, develop insu-
lin resistance, have aberrant responses to glucose tol-
erance tests and insulin tolerance tests. Most mouse 
strains also respond to HFD with cardiac remodeling, 
which can be diagnosed with increased heart mass, car-
diomyocyte hypertrophy, and cardiac fibrosis [8]. Other 
publications indicate no murine cardiac dysfunction 
after lengthy HFD, although in this example the HFD 
hearts did respond with morphologic changes [27]. Fur-
thermore, it is becoming obvious that the type of fat in 
Fig. 10 The working model of the differential response to HFD by the B6 and MRL mouse strains. Black arrows represent protein level changes in 
the B6 hearts and green arrows indicate protein level changes in the MRL hearts
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a HFD will differentially affect cardiac morphology and 
function during periods of stress, increasing specific fat 
intake often proving beneficial [28]. In the current man-
uscript, the 12 weeks HFD B6 control mice display cer-
tain features of DCM, such as hypertrophy, functional 
changes and lipid accumulation. In contrast, the HFD 
MRL mouse hearts successfully metabolically adapted to 
the HFD and did not display any characteristics of DCM.
Conclusions
As diabetic cardiomyopathy (DCM) causes the major-
ity of diabetic mortality, identification of a novel mouse 
model which does not succumb to DCM is an important 
scientific finding. In contrast to the B6 mouse strain used 
as controls, 12 weeks of HFD did not cause cardiac fibro-
sis, hypertrophy or functional detriments in the MRL 
hearts. The MRL cardiac tissue successfully metabolically 
adapted to the 12 weeks HFD protocol.
There are many experiments currently underway to 
further identify the beneficial adaptation in MRL metab-
olism. The data gathered from all of these experiments 
will help identify therapeutic targets for patients suffering 
from DCM. These therapeutic targets are potentially in 
metabolic pathways, such as specific pAMPK and AMPK 
modulations in skeletal muscle and cardiac tissues.
Currently a longer—20  week—HFD protocol is being 
conducted. This will verify the MRL mouse strain’s resist-
ance to chronic HFD. These mice will also be subjected to 
acute insulin challenge to investigate tissue specific insu-
lin sensitivity and resistance and further the identification 
of tissue specific metabolic adaptations. Furthermore the 
tissues harvested from these mice will be analyzed for 
enzymatic activities of key metabolic enzymes, such as 
adipose triglyceride lipase, hormone sensitive lipase and 
citrate synthase.
Currently, we are also investigating the HFD-associated 
inflammation. The MRL mice are known to have dispa-
rate immune reactions in response to trauma [29, 30], 
even these MRL/MpJ mice that have an intact Fas signal-
ing pathway are susceptible to autoimmune phenotypes as 
they age [31, 32]. Because inflammation is a well-known 
component of HFD-induced metabolic pathologies this is 
a very important direction for future investigations.
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